182 related articles for article (PubMed ID: 34696930)
21. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.
Budde K; Rath T; Sommerer C; Haller H; Reinke P; Witzke O; Suwelack B; Baeumer D; May C; Porstner M; Arns W
Clin Nephrol; 2015 Jan; 83(1):11-21. PubMed ID: 25512099
[TBL] [Abstract][Full Text] [Related]
22. Everolimus: preventing organ rejection in adult kidney transplant recipients.
Dantal J
Expert Opin Pharmacother; 2012 Apr; 13(5):767-78. PubMed ID: 22404500
[TBL] [Abstract][Full Text] [Related]
23. Everolimus in de novo liver transplant recipients: a systematic review.
Tang CY; Shen A; Wei XF; Li QD; Liu R; Deng HJ; Wu YZ; Wu ZJ
Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):461-9. PubMed ID: 26459721
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
25. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.
Nashan B
Clin Transplant; 2013; 27 Suppl 25():16-29. PubMed ID: 23909498
[TBL] [Abstract][Full Text] [Related]
26. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.
Budde K; Zeier M; Witzke O; Arns W; Lehner F; Guba M; Jacobi J; Kliem V; Reinke P; Hauser IA; Vogt B; Stahl R; Rath T; Duerr M; Paulus EM; May C; Porstner M; Sommerer C;
Nephrol Dial Transplant; 2017 Jun; 32(6):1060-1070. PubMed ID: 28605781
[TBL] [Abstract][Full Text] [Related]
27. Recommendations of everolimus use in liver transplant.
Rubín Suárez A; Bilbao Aguirre I; Fernández-Castroagudin J; Pons Miñano JA; Salcedo Plaza M; Varo Pérez E; Prieto Castillo M
Gastroenterol Hepatol; 2017 Nov; 40(9):629-640. PubMed ID: 28743539
[TBL] [Abstract][Full Text] [Related]
28. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
29. Histopathologic impacts of everolimus introduction on kidney transplant recipients.
Nakamura T; Ushigome H; Takata T; Nakao T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
Transplant Proc; 2015 Apr; 47(3):630-4. PubMed ID: 25891700
[TBL] [Abstract][Full Text] [Related]
30. Everolimus for BKV nephropathy in kidney transplant recipients: a prospective, controlled study.
Bussalino E; Marsano L; Parodi A; Russo R; Massarino F; Ravera M; Gaggero G; Fontana I; Garibotto G; Zaza G; Stallone G; Paoletti E
J Nephrol; 2021 Apr; 34(2):531-538. PubMed ID: 32533451
[TBL] [Abstract][Full Text] [Related]
31. Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.
Tredger JM; Brown NW; Dhawan A
Drugs; 2008; 68(10):1385-414. PubMed ID: 18578558
[TBL] [Abstract][Full Text] [Related]
32. Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.
Meszaros M; Dubois V; Congy-Jolivet N; Hamada S; Thevenin C; Faure S; Boillot O; Kamar N; Pageaux GP; Del Bello A; Dumortier J
Liver Int; 2022 May; 42(5):1132-1143. PubMed ID: 35184373
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
[TBL] [Abstract][Full Text] [Related]
34. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
35. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial.
Gullestad L; Eiskjaer H; Gustafsson F; Riise GC; Karason K; Dellgren G; Rådegran G; Hansson L; Gude E; Bjørtuft Ø; Jansson K; Schultz HH; Solbu D; Iversen M
Transpl Int; 2016 Jul; 29(7):819-29. PubMed ID: 27067532
[TBL] [Abstract][Full Text] [Related]
37. Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR).
Brakemeier S; Arns W; Lehner F; Witzke O; Vonend O; Sommerer C; Mühlfeld A; Rath T; Schuhmann R; Zukunft B; Kroeger I; Porstner M; Budde K
PLoS One; 2019; 14(9):e0222730. PubMed ID: 31536556
[TBL] [Abstract][Full Text] [Related]
38. A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.
Chadban SJ; Eris JM; Kanellis J; Pilmore H; Lee PC; Lim SK; Woodcock C; Kurstjens N; Russ G;
Transpl Int; 2014 Mar; 27(3):302-11. PubMed ID: 24279685
[TBL] [Abstract][Full Text] [Related]
39. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
[TBL] [Abstract][Full Text] [Related]
40. Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.
Sommerer C; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Wolters HH; Suwelack B; Klehr HU; Hauser IA; Stangl M; Nadalin S; Dürr M; Porstner M; May C; Wimmer P; Witzke O; Lehner F
Clin Nephrol; 2016 Apr; 85(4):215-25. PubMed ID: 26932178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
